GLP1R and non-Hodgkin lymphoma: Recently, a similar study of hematologic malignancies among GLP-1 receptor agonist users reported a significantly reduced risk of numerous neoplasms, including multiple myeloma, MGUS, myeloproliferative neoplasms, myelodysplastic syndrome, non-Hodgkins lymphoma, myeloid and lymphoid leukemias.13